Last reviewed · How we verify
Potato starch
At a glance
| Generic name | Potato starch |
|---|---|
| Also known as | Resistant starch |
| Sponsor | University of Michigan Rogel Cancer Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients (PHASE2)
- A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial (PHASE2)
- Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer (NA)
- Resistant Potato Starch to Alleviate GWI (PHASE2)
- Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy (NA)
- Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain (PHASE3)
- The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin (NA)
- Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Potato starch CI brief — competitive landscape report
- Potato starch updates RSS · CI watch RSS
- University of Michigan Rogel Cancer Center portfolio CI